![](/images/graphics-bg.png)
Ruxolitinib for Therapy of Graft-versus-Host Disease
Joint Authors
Neumann, Thomas
Schneidewind, Laila
Weigel, Martin
Plis, Andrzej
Vaizian, Rem
Schmidt, Christian A.
Krüger, William
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-03-06
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Objective.
Steroid-resistant graft-versus-host disease (GvHD) is a major challenge after allogeneic stem cell transplantation and associated with significant morbidity and mortality.
There is no therapeutic standard defined beyond calcineurin inhibitors (CNI) and steroids.
Furthermore, some patients may have contraindications against CNI or high-dose steroids.
Efficacy of ruxolitinib against GvHD has been described recently.
Methods.
Ruxolitinib was used for treatment of acute or chronic GvHD in eight patients.
The patients either needed intensification of therapy or had contraindications against use of CNI or high-dose steroids.
Results.
Supplementation of therapy in acute GvHD with severe diarrhea with ruxolitinib was unsuccessful.
All these patients died from acute GvHD.
Introduction of ruxolitinib into therapy and relapse prophylaxis in other patients was successful in 4/4 cases (CR=3, PR=1).
Indications for ruxolitinib were contraindications against CNI due to aHUS in two cases and the need for steroid sparing in two other cases.
None of these patients suffered from diarrhea at the initiation of ruxolitinib.
Conclusion.
Ruxolitinib was effective for therapy of acute and chronic GvHD in higher lines in patients without severe diarrhea.
Ruxolitinib could replace successfully CNI and high-dose steroids.
Further investigations are necessary to define the position of ruxolitinib in GvHD-therapy.
American Psychological Association (APA)
Neumann, Thomas& Schneidewind, Laila& Weigel, Martin& Plis, Andrzej& Vaizian, Rem& Schmidt, Christian A.…[et al.]. 2019. Ruxolitinib for Therapy of Graft-versus-Host Disease. BioMed Research International،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1127761
Modern Language Association (MLA)
Neumann, Thomas…[et al.]. Ruxolitinib for Therapy of Graft-versus-Host Disease. BioMed Research International No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1127761
American Medical Association (AMA)
Neumann, Thomas& Schneidewind, Laila& Weigel, Martin& Plis, Andrzej& Vaizian, Rem& Schmidt, Christian A.…[et al.]. Ruxolitinib for Therapy of Graft-versus-Host Disease. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1127761
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1127761